Fda - Articles - Page 2 | CARLAT PUBLISHING

Clinical Update

Six Recent Disappointments in Psychiatric Research

February 1, 2024

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.

Psychopharm Commandment 7B: Red Flags & Controlled Meds

April 10, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

More red flags to watch for when prescribing controls, and how to manage them in practice.

The Adderall Shortage

January 22, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

Adderall is in short supply, and the backlog is having a domino effect on other stimulants. Find out why, and how long it will last.

RESEARCH UPDATE

Less Sleep Correlated with Dementia

October 1, 2022

Talya Shahal, MD.

Talya Shahal, MD. Dr. Shahal, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study supports an association between short sleep duration in middle life and an increasedrisk of dementia.

In Brief: Meds in the Fast Lane

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.